脾多肽辅助治疗COPD急性加重期患者的临床疗效及安全性观察

目的：观察脾多肽辅助治疗慢性阻塞性肺疾病（COPD）急性加重期患者的临床疗效及安全性。方法选取89例COPD急性加重期患者，随机分为常规治疗组和脾多肽联合治疗组，前者采用常规综合治疗，后者给予脾多肽联合常规综合治疗，观察2组患者T淋巴细胞亚群、NK细胞及高敏C反应蛋白（hs-CRP）水平变化及临床疗效。结果2组患者治疗后 FEV1、FVC 及FEV1/FVC 均显著上升，脾多肽联合治疗组改善程度更为明显（P<0.05）。脾多肽联合治疗组总有效率为91.3%，常规治疗组为74.4%，2组比较差异有统计学意义（P<0.05）。 hs-CRP均显著下降，脾多肽联合治疗组下降更为明显（P<0.05）。脾多肽联合治疗组CD8+显著低于常规治疗组，CD4+、CD4+/CD8+显著高于常规治疗组（P均<0.05）。2组患者治疗中未出现明显的药物不良反应。结论脾多肽能够降低COPD急性加重期患者的炎性反应，调节其免疫水平，提高疗效。

Observation of clinical efficacy of Lienal polypeptide as the adjuvant therapy for the patients with acute exacerbation chronic obstructive pulmonary disease

Objective To investigate the effect of Lienal polypeptide as the adjuvant therapy for the patients with acute exacerbation chronic obstructive pulmonary disease (AECOPD). Methods Eighty-night patients with AECOPD in our hospital were randomly divided into two groups: regular therapy group (RTG) and combined therapy group (CTG). The former take routine comprehensive therapy, the latter take Lienal polypeptide with conventional comprehensive therapy. The levels of T lymphocyte subsets、NK cells and high-sensitivity C-reactive protein (hs-CRP) were tested and compared between the two groups. The clinical effect was also compared. Results The levels of FEV1, FVC and FEV1 /FVC in-creased significantly after the treatment in both groups, and the improvement was more pronounced in the CTG than in the RTG (P<0.05). The total effective rate was 91.3%in the CTG and 74.4%in the RTG. The level of hs-CRP was signifi-cantly decreased, and the decline was more obvious in the CTG (P<0.05). Compared with the RTG, the CD8+was obvi-ous lower and the CD4+、CD4+/CD8+were obvious higher in the CTG. There was no obvious adverse reaction occurred dur-ing treatment and follow-up. Conclusion Lienal polypeptide can reduce the inflammatory response, regulate the im-mune level and improve the curative effect in the patients with AECOPD.